Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
CAMPASS
A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)
- NCT04964479 ↗
- Unknown
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on CAMPASS (benmelstobart plus anlotinib in PD-L1-positive advanced non-small-cell lung cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on CAMPASS so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 9 posts on X |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Blind, Parallel Controlled, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Pembrolizumab Injection as a First-line Treatment on Patient With Advanced NSCLC.
- Phase
- Phase 3
- Status
- Unknown
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- TQB2450 injection; Anlotinib Hydrochloride Capsules; Pembrolizumab injection; Placebo
- Arms
- TQB2450 injection + Anlotinib Hydrochloride capsules · Experimental
- Pembrolizuma injection + placebo of Anlotinib hydrochloride capsules · Active comparator
- Enrollment
- 375 (estimated)
- Primary outcomes
- Disease progression-free survival(PFS) evaluated by Independent Review Committee (IRC)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Start
- Aug 6, 2021
- Primary completion
- Dec 2022 (estimated)
- Results posted
- No
- Registry record
- NCT04964479 · updated Aug 20, 2021
Publications
linked from the registry- Zhong H, Wang J, Yang R, Luo Y, Zuo W, Zhang W, Xie C, Li Q, Liu Q, Xu X, Wang Q, Yu Y, Chen Y, Yi T, Min X, Shi J, Yang J, Sun H, Chen H, Shi H, Gao J, Shi J, Zhang B, Chu T, Li K, Han B; CAMPASS Investigators. Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial. Lancet Oncol. 2026 Apr;27(4):419-431. doi: 10.1016/S1470-2045(26)00049-5. Epub 2026 Mar 10. PubMed 41825453
- Zhang W, Wang J, Wang Q, Cheng Y, Yang L, Li Y, Zhong H, Chu T, Dong Y, Zhang Y, Qian F, Xiong L, Shi C, Zhang C, He Z, Zhu J, Liu X, Ma H, Li K, Han B. A randomized double-blind trial of TQB2450 with or without anlotinib in pretreated driver-negative non-small cell lung cancer. Lung Cancer. 2023 Oct;184:107353. doi: 10.1016/j.lungcan.2023.107353. Epub 2023 Aug 21. PubMed 37647728